BrightGene Capital Lease Obligations from 2010 to 2025

688166 Stock   30.92  1.21  4.07%   
BrightGene Bio's Capital Lease Obligations is increasing over the years with slightly volatile fluctuation. Overall, Capital Lease Obligations is expected to go to about 25.4 M this year. Capital Lease Obligations is the total obligations of BrightGene Bio Medical under capital leases, which are lease agreements that transfer substantially all risks and rewards of ownership to the lessee. View All Fundamentals
 
Capital Lease Obligations  
First Reported
2010-12-31
Previous Quarter
24.2 M
Current Value
25.4 M
Quarterly Volatility
9.4 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check BrightGene Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BrightGene Bio's main balance sheet or income statement drivers, such as Tax Provision of 14.9 M, Interest Income of 21.7 M or Interest Expense of 53.6 M, as well as many indicators such as . BrightGene financial statements analysis is a perfect complement when working with BrightGene Bio Valuation or Volatility modules.
  
This module can also supplement various BrightGene Bio Technical models . Check out the analysis of BrightGene Bio Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in BrightGene Stock

BrightGene Bio financial ratios help investors to determine whether BrightGene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BrightGene with respect to the benefits of owning BrightGene Bio security.